N/A
N=138
BullyDown, a Text Messaging-based Bullying Prevention Program for Middle School-aged Youth
Bullying
Bottom Line
View on ClinicalTrials.gov: NCT06017050 ↗Enrolled (actual)
138
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Feasibility: Recruitment Rate — 202 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- BullyDown (Behavioral); Attention-matched control (Behavioral)
- Age
- Pediatric · 12+ yrs
- Sex
- All
- Sponsor
- Center for Innovative Public Health Research
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility: Recruitment Rate |
202 | — |
| PRIMARY Acceptability of the Intervention |
3.7; 3.6 | — |
| PRIMARY Feasibility: Retention at 3-month Follow-up |
48; 49 | — |
| SECONDARY Feasibility: Retention Rate at Program End |
59; 56 | — |
Summary
Given the limited impact of existing school-based interventions and the time associated with implementing them during school time, more efficient and effective intervention methods are needed. Programs that can be delivered to middle school youth irrespective of whether they are attending school physically or virtually may be especially relevant as school boundaries become more fluid. BullyDown addresses this critical need by providing a scalable program that could be quickly and cost-effectively disseminated nationally.
Eligibility Criteria
Participants will: be enrolled in one of our partner schools, be in middle school (i.e., 7th or 8th grade) or between the ages of 12-14 years of age, be English-speaking, own their own cell phone, intend to have the same cell phone number for at least 3 months (this may or may not apply, depending on the number of youth who meet this criterion), and provide informed written assent. Non-English speakers and youth who do not have the reading ability to complete the screener are not eligible. Youth recruited from schools will also be required to have parental permission.
Data sourced from ClinicalTrials.gov (NCT06017050). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.